Concepedia

Erin Jensen

EJ

Statistics

Publications

36

Citations

4.2K

H-Index

23

Active since

2001

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

University of California, San Francisco

Westmead Hospital

The University of Sydney

Erin Jensen is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and oncology.

Publications per year

2001–2024

36

Publications

36

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2021 · 1.1K citations · Full text

, , +17

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina Chiara Garassino, Shirish M. Gadgeel, Giovanna Speranza et al. · Journal of Clinical Oncology · 2023 · 643 citations · Full text

, , +16

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Silvia Novello, Dariusz M. Kowalski, Alexander Luft et al. · Journal of Clinical Oncology · 2023 · 512 citations · Full text

, , +17

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim et al. · Journal of Thoracic Oncology · 2021 · 312 citations · Full text

, , +16

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2020 · 281 citations · Full text

, , +17

1–5 of 36